Serotype-structured force of infection for optimizing dengue vaccine trial design
- 1Kisii University
Abstract
Dengue fever, transmitted primarily by Aedes aegypti, remains a major global public health threat, causing an estimated 390 million infections annually. Designing efficient dengue vaccine efficacy trials in endemic regions is challenging because transmission intensity varies across space and time, baseline population immunity is heterogeneous, and endpoint accrual depends strongly on the local force of infection (FoI). We developed a simulation framework for trial planning in endemic settings that links FoI to age-specific seroprevalence through a catalytic model and then translates FoI into symptomatic endpoint incidence for randomized controlled trial simulations. Across a range of FoI scenarios representing low-to-high endemic transmission, we evaluated sample size requirements, follow-up duration, and expected power under alternative vaccine efficacy assumptions. In high-transmission settings, the framework indicates that trials enrolling 5,000-10,000 participants per arm can achieve at least 80% power within 12-24 months of follow-up under plausible symptomatic detection assumptions. Sensitivity analyses demonstrate that feasibility thresholds are most sensitive to FoI and the symptomatic fraction, highlighting the importance of site selection and surveillance intensity. Overall, the proposed FoI-based approach provides practical guidance for dengue trial design, including sample size determination, follow-up planning, and the identification of epidemiological conditions under which vaccine evaluation is most efficient in endemic settings.
Related
- Association of dengue severity with the serotype of infection: a systematic review and meta-analysis
- Dengue vaccines and serotype complexity: Why India needs a calibrated strategy.
- Overall and serotype-specific dengue virus transmission intensity in Mexico, 2016–2023: A modelling study of case-notification data
- Necrotizing Fasciitis Caused by Serotype 7C Streptococcus pneumoniae in Overwhelming Post-splenectomy Infection
- Early warning of serotype replacement, spatial risk redistribution, and shifting clinical phenotypes: Insights from the 2023–2025 dengue outbreak in Meta, Colombia
BibTeX
@misc{agasa2026serotypestructured,
title = {{Serotype-structured force of infection for optimizing dengue vaccine trial design}},
author = {L. O. Agasa and F. M. Thuita and T. Achia and W. K. Cheruiyot and A. Karanja and D. A. Makambi},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.01.26367012},
url = {https://www.medrxiv.org/content/10.64898/2026.11.01.26367012v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Serotype-structured force of infection for optimizing dengue vaccine trial design
AU - L. O. Agasa
AU - F. M. Thuita
AU - T. Achia
AU - W. K. Cheruiyot
AU - A. Karanja
AU - D. A. Makambi
PY - 2026
DA - 2026/11/01
PB - medRxiv
DO - 10.64898/2026.11.01.26367012
UR - https://www.medrxiv.org/content/10.64898/2026.11.01.26367012v1
AB - Dengue fever, transmitted primarily by Aedes aegypti, remains a major global public health threat, causing an estimated 390 million infections annually. Designing efficient dengue vaccine efficacy trials in endemic regions is challenging because transmission intensity varies across space and time, baseline population immunity is heterogeneous, and endpoint accrual depends strongly on the local force of infection (FoI). We developed a simulation framework for trial planning in endemic settings that links FoI to age-specific seroprevalence through a catalytic model and then translates FoI into symptomatic endpoint incidence for randomized controlled trial simulations. Across a range of FoI scenarios representing low-to-high endemic transmission, we evaluated sample size requirements, follow-up duration, and expected power under alternative vaccine efficacy assumptions. In high-transmission settings, the framework indicates that trials enrolling 5,000-10,000 participants per arm can achieve at least 80% power within 12-24 months of follow-up under plausible symptomatic detection assumptions. Sensitivity analyses demonstrate that feasibility thresholds are most sensitive to FoI and the symptomatic fraction, highlighting the importance of site selection and surveillance intensity. Overall, the proposed FoI-based approach provides practical guidance for dengue trial design, including sample size determination, follow-up planning, and the identification of epidemiological conditions under which vaccine evaluation is most efficient in endemic settings.
ER -